Unknown

Dataset Information

0

Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors.


ABSTRACT: Class 2 CRISPR-Cas systems endow microbes with diverse mechanisms for adaptive immunity. Here, we analyzed prokaryotic genome and metagenome sequences to identify an uncharacterized family of RNA-guided, RNA-targeting CRISPR systems that we classify as type VI-D. Biochemical characterization and protein engineering of seven distinct orthologs generated a ribonuclease effector derived from Ruminococcus flavefaciens XPD3002 (CasRx) with robust activity in human cells. CasRx-mediated knockdown exhibits high efficiency and specificity relative to RNA interference across diverse endogenous transcripts. As one of the most compact single-effector Cas enzymes, CasRx can also be flexibly packaged into adeno-associated virus. We target virally encoded, catalytically inactive CasRx to cis elements of pre-mRNA to manipulate alternative splicing, alleviating dysregulated tau isoform ratios in a neuronal model of frontotemporal dementia. Our results present CasRx as a programmable RNA-binding module for efficient targeting of cellular RNA, enabling a general platform for transcriptome engineering and future therapeutic development.

SUBMITTER: Konermann S 

PROVIDER: S-EPMC5910255 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors.

Konermann Silvana S   Lotfy Peter P   Brideau Nicholas J NJ   Oki Jennifer J   Shokhirev Maxim N MN   Hsu Patrick D PD  

Cell 20180315 3


Class 2 CRISPR-Cas systems endow microbes with diverse mechanisms for adaptive immunity. Here, we analyzed prokaryotic genome and metagenome sequences to identify an uncharacterized family of RNA-guided, RNA-targeting CRISPR systems that we classify as type VI-D. Biochemical characterization and protein engineering of seven distinct orthologs generated a ribonuclease effector derived from Ruminococcus flavefaciens XPD3002 (CasRx) with robust activity in human cells. CasRx-mediated knockdown exhi  ...[more]

Similar Datasets

| S-EPMC7955661 | biostudies-literature
| S-EPMC5999320 | biostudies-literature
| S-EPMC8209922 | biostudies-literature
| S-EPMC7613696 | biostudies-literature
| S-EPMC4078801 | biostudies-literature
| S-EPMC7757703 | biostudies-literature
| S-EPMC5935466 | biostudies-literature
| S-EPMC8789034 | biostudies-literature
| S-EPMC3146020 | biostudies-literature
| S-EPMC3652678 | biostudies-literature